Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
· cnbc.com
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced W...